STANDARD BIOTOOLS INC. (LAB) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($46.9K bought vs $0 sold). Latest close $0.57 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 5, 2026 · Congress to Nov 16, 2026.
Viking Global Investors — 1 tracked fund hold LAB. See all holders.
Insiders bought on the open market (1 purchase, $46.9K) vs 0 sales ($0). Latest buy: Nov 5, 2026. Insider trading
Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Viking Global Investors | 0.14% | 58,651,170 | HELD Q3 filed Nov 16 |
| Slate Path Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -38.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
| Institutions holding | 142 of 8,857 filers |
| Long-only filers among them | 142 |
| Change vs 2026 Q1 | -7 net · 139 entered · 146 exited |
| Shares reported, all filers | 295,769,374 |
| Reported value, all filers | $242.2M |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations (SIC 2834) |
| Revenue · FY2025 | $85.3M |
| Net income · FY2025 | $-74.9M |
| Total assets · FY2025 | $567.8M |
| Shares outstanding | 392,578,808 |
| Market cap (at latest close) | $223.8M |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.
| Shares short · Oct 15, 2026 | 2,445,793 |
| Share of shares outstanding | 0.62% |
| Days to cover | 2.50 |
Shares short at recent settlements — Jul 31, 2026: 2.7M · Aug 14, 2026: 2.4M · Aug 31, 2026: 3.0M · Sep 15, 2026: 2.6M · Sep 30, 2026: 2.5M · Oct 15, 2026: 2.4M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 320 · Aug 14, 2026: 0 · Aug 31, 2026: 8K · Sep 15, 2026: 11 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.
1 insider bought on the open market in the last 90 days (1 purchase, $46.9K), against 0 sales by 0 insiders ($0). Latest buy: Nov 5, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| Carey Thomas D. · 75,000 shares on Nov 5, 2026 · filed Nov 5, 2026 | $0.63 | -15.7% (close Nov 6, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Nov 6, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | Carey Thomas D. | Buy | 75,000 | $0.63 | $46.9K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| May 23, 2025 | Mackay Sean | Officer | 13,217 | $12.4K | May 23, 2025 | SEC filing |
| May 23, 2025 | Kim Hanjoon Alex | Officer | 1,428 | $1.3K | May 23, 2025 | SEC filing |
| May 23, 2025 | Egholm Michael | Officer, Director | 5,473 | $5.2K | May 23, 2025 | SEC filing |
| May 22, 2025 | Egholm Michael | Officer, Director | 5,116 | $5.1K | May 22, 2025 | SEC filing |
| May 22, 2025 | Mackay Sean | Officer | 12,536 | $12.6K | May 22, 2025 | SEC filing |
| May 22, 2025 | Kim Hanjoon Alex | Officer | 1,355 | $1.4K | May 22, 2025 | SEC filing |
| May 21, 2025 | Kim Hanjoon Alex | Officer | 1,407 | $1.5K | May 21, 2025 | SEC filing |
| May 21, 2025 | Mackay Sean | Officer | 12,838 | $13.2K | May 21, 2025 | SEC filing |
| May 21, 2025 | Egholm Michael | Officer, Director | 4,719 | $4.9K | May 21, 2025 | SEC filing |
| Nov 12, 2024 | Black Jeffrey G. | Former Officer | 57,971 | $123.1K | Nov 12, 2024 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Form | Price change since disclosure |
|---|---|---|
| Jun 12, 2026 | SCHEDULE 13D | -36.5% (close Jun 15, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Jun 15, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | MAK CAPITAL ONE LLC | SC 13G/A | 28,813,904 | 7.3% | Jun 30, 2026 | SEC filing |
| Aug 14, 2026 | LONG FOCUS CAPITAL MANAGEMENT, LLC | SC 13G | 23,500,000 | 6.0% | Jun 30, 2026 | SEC filing |
| Jul 30, 2026 | BlackRock, Inc. | SC 13G/A | 7,911,347 | 2.0% | Jun 30, 2026 | SEC filing |
| Jun 12, 2026 | VIKING GLOBAL INVESTORS LP | SC 13D | 58,651,170 | 15.0% | Jun 6, 2026 | SEC filing |
| Jun 9, 2026 | Casdin Capital, LLC | SC 13D/A | 88,783,856 | 22.7% | Jun 6, 2026 | SEC filing |
| May 15, 2026 | MAK Capital Fund LP | SC 13G/A | 26,172,626 | 6.7% | Mar 31, 2026 | SEC filing |
| May 15, 2026 | VIKING GLOBAL INVESTORS LP | SC 13G/A | 58,651,170 | 15.0% | Mar 31, 2026 | SEC filing |
| Jan 7, 2026 | MAK Capital Fund LP | SC 13G | 19,967,565 | 5.2% | Dec 31, 2025 | SEC filing |
| Nov 28, 2025 | Casdin Capital, LLC | SC 13D/A | 88,433,856 | 22.9% | Nov 25, 2025 | SEC filing |
| Mar 4, 2025 | Casdin Capital, LLC | SC 13D/A | 76,075,636 | 20.4% | Feb 28, 2025 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).
Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Insiders
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
Financial Screens
· Net-Net (NCAV) — Market cap below net current asset value
Red Flags
· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10
· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)
Key figures
· Net-Net (NCAV) — NCAV: $310.8M · Market cap: $236.6M · NCAV / market cap: 1.31
· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $46.9K · Latest buy: Nov 5, 2026
· Distress Risk (Altman Z″) — Z″-Score: -1.44 · Working capital / assets: 0.61 · Retained earnings / assets: -2.22 · EBIT / assets: -0.19 · Equity / liabilities: 2.96
· Late Filings (NT) — Latest event: Aug 12, 2025 · Events in 2 yrs: 1 · Latest form: NT 10-Q
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q2, ranked #33 of 50.
Also held by the tracked funds that hold LAB — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).
8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.
| Filed | Items | Source |
|---|---|---|
| Nov 16, 2026 | 8.01 Other Events | SEC filing |
| Nov 3, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 5, 2026 | 7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on LAB
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.